Prognostic significance of antrum‐predominant gastritis in functional dyspepsia

Heikkinen, Markku; Vornanen, Martine; Hollmén, Sinikka; Färkkilä, Martti

doi:10.1080/00365520310008287

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a long-term study of 182 dyspeptic patients who underwent upper gastrointestinal endoscopy with biopsies [18], approximately 75% were asymptomatic after a 6-to 7-year follow-up, and this was not influenced by the presence of gastritis. Patients with antrum-predominant gastritis were more likely to develop peptic ulcer during the follow-up period.…”

Section: Role Of Helicobacter Pylorimentioning

confidence: 97%

Pathogenesis and therapy for idiopathic dyspepsia

Tack

Kindt

2005

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Functional dyspepsia (FD) is one of the most common gastrointestinal disorders. This review summarizes recent progress in our understanding of the pathogenesis and therapy for FD. Although distinction among FD, irritable bowel syndrome, and reflux disease is difficult in population-based studies, separate entities can be recognized in patients who seek medical attention. The pathogenesis of FD remains unclear, but recent studies have demonstrated a role for acute gastrointestinal infection in triggering FD and in genetic polymorphisms of G-proteins in predisposing to FD. The role of abnormalities in gastric motor function, visceral hypersensitivity, and psychosocial factors in the pathophysiology of dyspeptic symptoms has been the topic of multiple studies. Treatment options for FD remain limited. Recent studies have focused on acid-suppressive drugs and on novel prokinetics. Progress in our understanding of the pathogenesis and pathophysiology of FD may lead to new or improved treatment modalities. Areas of major advances are the role of infection and genetic predisposition and studies on the role of abnormalities in gastric motility and sensitivity.

show abstract

Section: Role Of Helicobacter Pylorimentioning

confidence: 97%

Pathogenesis and therapy for idiopathic dyspepsia

Tack

Kindt

2005

Curr Gastroenterol Rep

View full text Add to dashboard Cite

show abstract

“…In some studies, authors tried to identify subgroups of patients with NUD who might show a major benefit from H. pylori eradication. Finnish researchers revealed that antrum‐predominant gastritis in NUD patients seems to carry an increased risk for PU [24]. An Italian group found that in H. pylori ‐positive NUD patients during a 1 year follow‐up, DU developed in 12 (22.6%) patients with duodenal colonization and only in two (1.6%) without (OR = 6.29; 95% CI = 2.4–17.4) [25].…”

Section: H Pylori and Non‐ulcer Dyspepsiamentioning

confidence: 99%

Helicobacter pylori and Non‐malignant Diseases

Kupčinskas

Malfertheiner

2005

Helicobacter

View full text Add to dashboard Cite

This paper reviews new literature data from March 2004 to April 2005 about the association between Helicobacter pylori and non-malignant disease of the upper gastrointestinal tract. Eradication of H. pylori is indicated for all patients with non-malignant diseases associated with this pathogen. However, its effect is variable, ranging from the highest benefit in the cure of peptic ulcer disease to a small benefit in patients with non-ulcer dyspepsia. Test and treat strategy is still cost-effective for management of patients with uninvestigated dyspepsia. The only limitations of the strategy are the patient's age and the cost benefit ratio in case of low prevalence of the infection. H. pylori eradication is of value in chronic NSAID users, but is insufficient to prevent NSAID-related ulcer disease. In developed countries H. pylori eradication does not cause gastro-esophageal reflux disease (GORD), however, a negative association between H. pylori and GORD does exist, especially in Asia, but the nature of this relationship should be further clarified.

show abstract